Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng; Ryuhei Okada; Hisataka Kobayashi; Tadanobu Nagaya; Junxia Wei; Qi Zhou; Fred Lee; Tapan K. Bera; Yun Gao; William Kuhlman; Chin-Hsien Tai; Ira Pastan

doi:10.1158/1535-7163.MCT-19-0890

Large Molecule Therapeutics

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan

Zeliang Zheng

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ryuhei Okada

2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Ryuhei Okada

Hisataka Kobayashi

2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tadanobu Nagaya

2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Junxia Wei

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Qi Zhou

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Fred Lee

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tapan K. Bera

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yun Gao

3Selecta Biosciences, Watertown, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

William Kuhlman

3Selecta Biosciences, Watertown, Massachusetts.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chin-Hsien Tai

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ira Pastan

1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Ira Pastan
For correspondence: pastani@mail.nih.gov

DOI: 10.1158/1535-7163.MCT-19-0890 Published March 2020

Article
Figures & Data
Info & Metrics
PDF

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

March 2020
Volume 19, Issue 3

Table of Contents
Table of Contents (PDF)
About the Cover
Editorial Board (PDF)

Search for this keyword

View this article with LENS

Open full page PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Message Subject (Your Name) has forwarded a page to you from Molecular Cancer Therapeutics

Message Body (Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan

Mol Cancer Ther March 1 2020 (19) (3) 812-821; DOI: 10.1158/1535-7163.MCT-19-0890

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan

Mol Cancer Ther March 1 2020 (19) (3) 812-821; DOI: 10.1158/1535-7163.MCT-19-0890

Share This Article: